Follow
Hans Olav Melberg
Title
Cited by
Cited by
Year
Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries
JE Bekelman, SD Halpern, CR Blankart, JP Bynum, J Cohen, R Fowler, ...
Jama 315 (3), 272-283, 2016
509*2016
A new proposal for priority setting in Norway: open and fair
T Ottersen, R Førde, M Kakad, A Kjellevold, HO Melberg, A Moen, ...
Health policy 120 (3), 246-251, 2016
1122016
Addiction: choice or compulsion?
E Henden, HO Melberg, O Rogeberg
Frontiers in psychiatry 4, 53187, 2013
792013
Is cannabis a gateway to hard drugs?
HO Melberg, AM Jones, AL Bretteville-Jensen
Empirical Economics 38, 583-603, 2010
792010
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
DN Rasmussen, M Thiele, S Johansen, M Kjærgaard, KP Lindvig, ...
Journal of hepatology 75 (5), 1017-1025, 2021
782021
European regional differences in all‐cause mortality and length of stay for patients with hip fracture
E Medin, F Goude, HO Melberg, F Tediosi, E Belicza, M Peltola, ...
Health economics 24, 53-64, 2015
722015
Sequential patterns of drug use initiation-Can we believe in the gateway theory?
AL Bretteville-Jensen, HO Melberg, AM Jones
The BE Journal of Economic Analysis & Policy 8 (2), 2008
582008
Hvilken nytte, for hvem og til hvilken kostnad? En prospektiv studie av stoffmisbrukere i behandling
HO Melberg, GO Lauritzen, E Ravndal
532003
Do smoke-free laws affect revenues in pubs and restaurants?
HO Melberg, KE Lund
The European Journal of Health Economics 13, 93-99, 2012
462012
Cost‐effectiveness of noninvasive screening for alcohol‐related liver fibrosis
L Asphaug, M Thiele, A Krag, HO Melberg
Hepatology 71 (6), 2093-2104, 2020
452020
Measuring the harm of illicit drug use on friends and family
HO Melberg, P Hakkarainen, E Houborg, M Jääskeläinen, A Skretting, ...
Nordic Studies on Alcohol and Drugs 28 (2), 105-121, 2011
422011
Ineligibility and refusal to participate in randomised trials of treatments for drug dependence
HO Melberg, K Humphreys
Drug and alcohol review 29 (2), 193-201, 2010
382010
The cost-effectiveness of multigene panel testing for hereditary breast and ovarian cancer in Norway
L Asphaug, HO Melberg
MDM policy & practice 4 (1), 2381468318821103, 2019
342019
Integration, alienation, and conflict in Estonia and Moldova at the societal level: A comparison
P Kolstø, HO Melberg
National integration and violent conflict in Post-Soviet societies: The …, 2002
322002
The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission
J Burisch, M Zhao, S Odes, P De Cruz, S Vermeire, CN Bernstein, ...
The Lancet Gastroenterology & Hepatology 8 (5), 458-492, 2023
312023
Study-design selection criteria in systematic reviews of effectiveness of health systems interventions and reforms: a meta-review
PC Rockers, AB Feigl, JA Røttingen, A Fretheim, D de Ferranti, JN Lavis, ...
Health Policy 104 (3), 206-214, 2012
302012
Three problems with the ASI composite scores
H Olav Melberg
Journal of Substance Use 9 (3-4), 120-126, 2004
302004
Liggetider og reinnleggelser i somatiske sykehus før og etter Samhandlingsreformen
HO Melberg, TP Hagen
Tidsskrift for omsorgsforskning 2 (2), 143-158, 2016
292016
Becker’s rational addiction theory: an empirical test with price elasticities for distilled spirits in Denmark 1911–31
OJ Skog, HO Melberg
Addiction 101 (10), 1444-1450, 2006
282006
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial
M Israelsen, BS Madsen, N Torp, S Johansen, CD Hansen, S Detlefsen, ...
The Lancet Gastroenterology & Hepatology 8 (6), 523-532, 2023
262023
The system can't perform the operation now. Try again later.
Articles 1–20